Human DLG4/PSD95/SAP-90 ORF/cDNA clone-Lentivirus particle (NM_001128827)

Cat. No.: vGMLP003314

Pre-made Human DLG4/PSD95/SAP-90 Lentiviral expression plasmid for DLG4 lentivirus packaging, DLG4 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.

Target products collection

Go to DLG4/PSD95 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name lentivirus Grade lentivirus quantity
vGMLP003314 Human DLG4 Lentivirus particle Pilot Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
Research Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMLP003314
Gene Name DLG4
Accession Number NM_001128827
Gene ID 1742
Species Human
Product Type Lentivirus particle (overexpression)
Insert Length 2166 bp
Gene Alias PSD95,SAP-90,SAP90
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGGACTGTCTCTGTATAGTGACAACCAAGAAATACCGCTACCAAGATGAAGACACGCCCCCTCTGGAGCACAGCCCGGCCCACCTCCCCAACCAGGCCAATTCTCCCCCAGTGATTGTCAACACAGATACCCTAGAAGCCCCAGGATATGTGAACGGGACCGAGGGGGAGATGGAATACGAGGAAATCACATTGGAAAGGGGTAACTCAGGTCTGGGCTTCAGCATCGCAGGTGGCACTGACAACCCACACATCGGTGACGACCCATCCATTTTCATCACCAAGATCATTCCTGGTGGGGCTGCGGCCCAGGATGGCCGCCTCAGGGTCAACGACAGCATCCTGTTTGTAAATGAAGTGGACGTGCGCGAGGTGACCCACTCAGCGGCGGTGGAAGCCCTCAAAGAGGCAGGCTCCATCGTTCGCCTCTATGTCATGCGCCGGAAGCCCCCGGCTGAGAAGGTCATGGAGATCAAGCTCATCAAGGGGCCTAAAGGTCTTGGCTTCAGCATCGCAGGGGGCGTAGGGAACCAGCACATCCCAGGAGATAATAGCATCTATGTAACAAAGATCATCGAAGGGGGTGCTGCCCACAAGGATGGGAGGTTGCAGATTGGAGACAAGATCCTGGCGGTCAACAGTGTGGGGCTAGAGGACGTCATGCATGAAGATGCTGTGGCAGCCCTGAAGAACACGTATGATGTTGTCTACCTAAAGGTGGCCAAGCCCAGCAATGCCTACCTGAGTGACAGCTATGCTCCCCCAGACATCACAACCTCTTATTCCCAGCACCTGGACAATGAGATCAGTCACAGCAGCTACCTGGGCACCGACTACCCCACAGCCATGACCCCCACTTCCCCTCGGCGCTACTCTCCAGTGGCCAAGGACCTGCTCGGGGAGGAAGACATTCCCCGAGAACCGAGGCGAATTGTGATCCACCGGGGCTCCACGGGCCTGGGCTTCAACATCGTGGGTGGCGAGGACGGTGAAGGCATCTTCATCTCCTTTATCCTGGCCGGGGGCCCTGCAGACCTCAGTGGGGAGCTGCGGAAGGGGGACCAGATCCTGTCGGTCAACGGTGTGGACCTCCGAAATGCCAGCCATGAGCAGGCTGCCATTGCCCTGAAGAATGCGGGTCAGACGGTCACGATCATCGCTCAGTATAAACCAGAAGAGTACAGCCGATTCGAGGCCAAGATCCACGACCTTCGGGAACAGCTCATGAACAGCAGCCTGGGCTCAGGGACTGCGTCCCTGCGGAGCAACCCCAAAAGGGGTTTCTACATCAGGGCCCTGTTTGATTACGACAAGACCAAGGACTGCGGCTTCCTGAGCCAGGCCCTGAGCTTCCGCTTTGGGGATGTGCTGCATGTCATCGATGCTAGTGATGAGGAGTGGTGGCAGGCACGGCGGGTCCACTCTGACAGTGAGACCGACGACATTGGGTTCATCCCCAGCAAACGGCGGGTTGAGCGACGAGAGTGGTCAAGGTTAAAGGCCAAGGACTGGGGCTCCAGCTCTGGATCGCAGGGTCGAGAAGACTCGGTTCTGAGCTACGAGACAGTGACGCAGATGGAAGTGCACTATGCTCGCCCCATCATCATCCTTGGGCCCACCAAGGACCGCGCCAACGATGATCTTCTCTCCGAGTTCCCCGACAAGTTTGGATCCTGTGTTCCCCATACGACACGGCCCAAGCGGGAGTATGAGATAGATGGCCGGGATTACCACTTTGTGTCGTCCCGGGAGAAAATGGAGAAGGACATTCAGGCGCACAAGTTCATTGAGGCCGGCCAGTACAACAGCCACCTCTATGGGACCAGCGTCCAGTCCGTGCGAGAGGTGGCAGAGCAGGGGAAGCACTGCATCCTCGATGTCTCGGCCAATGCCGTGCGGCGGCTGCAGGCGGCCCACCTGCACCCCATCGCCATCTTCATCCGCCCCCGCTCCCTGGAGAATGTGCTAGAGATTAACAAGCGGATCACAGAGGAGCAAGCCCGCAAAGCCTTCGACAGAGCCACCAAGCTGGAGCAGGAGTTCACAGAGTGCTTCTCAGCCATCGTGGAGGGTGACAGCTTTGAGGAGATCTACCACAAGGTGAAGCGTGTCATCGAGGACCTCTCAGGCCCCTACATCTGGGTTCCAGCCCGAGAGAGACTCTGA
ORF Protein Sequence MDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYVNGTEGEMEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKDLLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGTASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDSETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIILGPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIEAGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLEINKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPARERL

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T04507-Ab Anti-DLG4/ PSD95/ SAP-90 monoclonal antibody
    Target Antigen GM-Tg-g-T04507-Ag DLG4 VLP (virus-like particle)
    ORF Viral Vector pGMLP003314 Human DLG4 Lentivirus plasmid
    ORF Viral Vector vGMLP003314 Human DLG4 Lentivirus particle


    Target information

    Target ID GM-T04507
    Target Name DLG4
    Gene Group Identifier
    （Target Gene ID in Homo species)         		1742
    Gene ID 100061544 (Equus caballus), 100137840 (Bos taurus), 101093902 (Felis catus), 13385 (Mus musculus)
    1742 (Homo sapiens), 29495 (Rattus norvegicus), 489462 (Canis lupus familiaris), 714273 (Macaca mulatta)
    Gene Symbols & Synonyms DLG4,Dlg4,Dlgh4,PSD95,SAP90,PSD-95,SAP90A,MRD62,SAP-90,Sap90
    Target Alternative Names DLG4,Disks large homolog 4,Dlg4,Dlgh4,MRD62,PSD-95,PSD95,Postsynaptic density protein 95 (PSD-95),SAP-90,SAP90,SAP90),SAP90A,Sap90,Synapse-associated protein 90 (SAP-90
    Uniprot Accession P31016,P78352,Q62108
    Additional SwissProt Accessions: Q62108,P78352,P31016
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target
    Disease
    Disease from KEGG Hippo signaling pathway, Glutamatergic synapse, Cocaine addiction
    Gene Ensembl ENSECAG00000024301, ENSBTAG00000002564, ENSMUSG00000020886, ENSG00000132535, ENSCAFG00845018777, ENSMMUG00000010536
    Target Classification


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.